Edition:
United Kingdom

RaQualia Pharma Inc (4579.T)

4579.T on Tokyo Stock Exchange

1,112JPY
17 Nov 2017
Change (% chg)

¥12 (+1.09%)
Prev Close
¥1,100
Open
¥1,100
Day's High
¥1,125
Day's Low
¥1,087
Volume
592,600
Avg. Vol
1,490,305
52-wk High
¥1,908
52-wk Low
¥371

Latest Key Developments (Source: Significant Developments)

RaQualia Pharma announces exercise of options
Monday, 16 Oct 2017 

Oct 16(Reuters) - RaQualia Pharma Inc <4579.T>:Says 1,000 units of its 14th series options were exercised to 1 million shares of its common stock, by Daiwa Securities Co. Ltd., during period from Oct. 10 to Oct. 16.  Full Article

RaQualia Pharma says exercise of options
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - RaQualia Pharma Inc <4579.T>:Says 180 units of its 14th series options were exercised to 180,000 shares of its common stock on Oct. 12.Says the shares were exercised at the price of 976.5 yen per share.  Full Article

RaQualia Pharma says exercise of options
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - RaQualia Pharma Inc <4579.T>:Says 100 units of its 14th series options were exercised to 100,000 shares of its stock on Oct. 11, at the price of 998.3 yen per share.  Full Article

RaQualia Pharma gets substance patent for ghrelin receptor agonist(serine derivative) in Japan
Thursday, 6 Oct 2016 

RaQualia Pharma Inc <4579.T>: Says it received substance patent for ghrelin receptor agonist(serine derivative) in Japan .Says the substance is used for improvement of anorexia and suppression of body weight reduction.  Full Article

RaQualia Pharma gets sodium channel blocker patent allowance in China
Friday, 23 Sep 2016 

RaQualia Pharma Inc <4579.T>:Says it received an allowance for sodium channel blocker substance patent in China (Application No.201380022248.1).  Full Article

RaQualia Pharma says sodium channel blocker patent allowance in China
Monday, 25 Jul 2016 

RaQualia Pharma Inc <4579.T>:Says the company received an allowance for a sodium channel blocker substance patent in China (Application Number: 201180050306.2, Arylamide derivatives).  Full Article

RaQualia Pharma receives patent recognition for sodium channel blocker from EU
Thursday, 7 Jul 2016 

RaQualia Pharma Inc <4579.T>: Says it received patent recognition for its sodium channel blocker from Europe .Says sodium channel blocker is a medicine used to relieve the pain.  Full Article

RaQualia Pharma gets FDA approval
Wednesday, 18 May 2016 

RaQualia Pharma Inc <4579.T>: Says the company received approval for Entyce from the U.S. Food and Drug Administration (FDA) in U.S. on May 17 .Says Entyce is for the treatment of dogs' anorexia.  Full Article

RaQualia Pharma says patent assessment for 5-HT2B antagonist in Korea
Wednesday, 20 Apr 2016 

RaQualia Pharma Inc:Says received decision for a patent grant to 5-HT2B antagonist in Korea.Says 5-HT2B receptors are widely distributed through-out the human intestinal tract and are thought to be a viable new target for irritable bowel syndrome (IBS) treatment.  Full Article

RaQualia Pharma enters joint research agreement with ASAHI KASEI PHARMA
Tuesday, 22 Mar 2016 

RaQualia Pharma Inc:Enters a joint research agreement with ASAHI KASEI PHARMA CORPORATION on March 22.Says the two entities to be engaged in joint research of new pharmaceuticals which take the specified ion channels as target.  Full Article

CORRECTED-OFFICIAL-BRIEF- RaQualia Pharma announces exercise of options

* Says 1,000 units of its 14th series options were exercised to 1 million shares of its common stock, by Daiwa Securities Co. Ltd., during period from Oct. 11 to Oct. 16